Biden Pulls Plug on Automatic Medicare Coverage for MCIT “Breakthrough” Devices by Glenn S. Demby | Sep 23, 2021 | Articles, Essential, National Lab Reporter, Reimbursement-nir... This content is for Paid Members only.RegisterAlready a member? Log in here
Final Rule Clarifies Liability for Off-Label Uses and Lab’s Right to Create LDTs by Glenn S. Demby | Sep 13, 2021 | Articles, Essential, FDA-lir, Laboratory Industry Report, LDTs-lir... This content is for Paid Members only.RegisterAlready a member? Log in here
Agency Imposes 2.5 Percent Increase in 2022 Premarket Application User Fees by Glenn S. Demby | Sep 6, 2021 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, FDA-dtet... This content is for Paid Members only.RegisterAlready a member? Log in here
New LCD Expanding Medicare Coverage for Circulating Tumor Cells Tests Is a Win for Biocept by Glenn S. Demby | Aug 23, 2021 | Articles, Clinical Diagnostics Insider, CMS-nir, Diagnostic Testing and Emerging Technologies, Industry Buzz-lir, Laboratory Industry Report, National Lab Reporter... This content is for Paid Members only.RegisterAlready a member? Log in here
FDA Watch: VALID and VITAL Bills for LDTs Regulation Are Back in Play by Glenn S. Demby | Aug 17, 2021 | Articles, Essential, FDA-lir, Laboratory Industry Report... This content is for Paid Members only.RegisterAlready a member? Log in here